Granules India share price: Sharekhan reiterates Buy recommendation with an unchanged price target of Rs 475
Granules India is witnessing a robust outlook across segments and the finished dosages (FD) segment is expected to be a key growth driver. Granules India is looking to increase contribution of the high-margin FD segment to 60% over the next the 2-3 years from 52% (FY2020) backed by a strong product pipeline and growth in existing business. Sharekhan reiterates Buy recommendation on Granules India with an unchanged price target of Rs 475.
Granules India is looking to add 23 new products across all dosage forms in FD segment over FY21- FY23. Also, it has relaunched Metformin in the US recently and has been able to quickly grab a 60% market share: Reuters